C. Lin Et Al. , "Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer," 43rd ESMO Congress (ESMO) , vol.29, Munich, Germany, pp.413, 2018
Lin, C. Et Al. 2018. Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. 43rd ESMO Congress (ESMO) , (Munich, Germany), 413.
Lin, C., Taylor, M., Boni, V., Brunsvig, P. F., Geater, S. L., Salvagni, S., ... Garrido Lopez, P.(2018). Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer . 43rd ESMO Congress (ESMO) (pp.413). Munich, Germany
Lin, C-C. Et Al. "Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer," 43rd ESMO Congress (ESMO), Munich, Germany, 2018
Lin, C-C. Et Al. "Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer." 43rd ESMO Congress (ESMO) , Munich, Germany, pp.413, 2018
Lin, C. Et Al. (2018) . "Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer." 43rd ESMO Congress (ESMO) , Munich, Germany, p.413.
@conferencepaper{conferencepaper, author={C-C. Lin Et Al. }, title={Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer}, congress name={43rd ESMO Congress (ESMO)}, city={Munich}, country={Germany}, year={2018}, pages={413} }